AR126457A1 - Inhibidores peptídicos bicíclicos del receptor de interleuquina-23 - Google Patents

Inhibidores peptídicos bicíclicos del receptor de interleuquina-23

Info

Publication number
AR126457A1
AR126457A1 ARP220101855A ARP220101855A AR126457A1 AR 126457 A1 AR126457 A1 AR 126457A1 AR P220101855 A ARP220101855 A AR P220101855A AR P220101855 A ARP220101855 A AR P220101855A AR 126457 A1 AR126457 A1 AR 126457A1
Authority
AR
Argentina
Prior art keywords
receptor
peptide inhibitors
interleukine
bicyclic peptide
interleukin
Prior art date
Application number
ARP220101855A
Other languages
English (en)
Spanish (es)
Inventor
Chengzao Sun
Sandeep Somani
Stephanie A Barros
Raymond J Patch
Santhosh Francis Neelamkavil
Jing Zhang
Charles Hendrick
Elisabetta Bianchi
Roberto Constante
Raffaele Ingenito
Danila Branca
Ashok Bhandari
Brian Frederick
Tran Trung Tran
Jie Zhang
Original Assignee
Janssen Biotech Inc
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Protagonist Therapeutics Inc filed Critical Janssen Biotech Inc
Publication of AR126457A1 publication Critical patent/AR126457A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
ARP220101855A 2021-07-14 2022-07-14 Inhibidores peptídicos bicíclicos del receptor de interleuquina-23 AR126457A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163221854P 2021-07-14 2021-07-14

Publications (1)

Publication Number Publication Date
AR126457A1 true AR126457A1 (es) 2023-10-11

Family

ID=84920518

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101855A AR126457A1 (es) 2021-07-14 2022-07-14 Inhibidores peptídicos bicíclicos del receptor de interleuquina-23

Country Status (12)

Country Link
US (1) US20240352073A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370532A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024525723A (cg-RX-API-DMAC7.html)
KR (1) KR20240034223A (cg-RX-API-DMAC7.html)
CN (1) CN117980320A (cg-RX-API-DMAC7.html)
AR (1) AR126457A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022310347A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226492A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000761A (cg-RX-API-DMAC7.html)
TW (1) TW202321275A (cg-RX-API-DMAC7.html)
UY (1) UY39858A (cg-RX-API-DMAC7.html)
WO (1) WO2023288017A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
EP4652181A1 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Polycyclic peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025076414A1 (en) * 2023-10-06 2025-04-10 The Children's Medical Center Corporation Compositions and methods for selecting a subject for inflammatory bowel disease treatment
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026815A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201810154WA (en) * 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016054445A1 (en) * 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
HK1257747A1 (zh) * 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
CA3046171A1 (en) * 2016-12-06 2018-06-14 Stichting Voor De Technische Wetenschappen Multicyclic peptides and methods for their preparation
WO2019034866A1 (en) * 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
MX2020006290A (es) * 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.
CA3104418A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2020311395A1 (en) * 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物

Also Published As

Publication number Publication date
EP4370532A4 (en) 2025-09-03
KR20240034223A (ko) 2024-03-13
TW202321275A (zh) 2023-06-01
CN117980320A (zh) 2024-05-03
UY39858A (es) 2023-02-28
JP2024525723A (ja) 2024-07-12
WO2023288017A3 (en) 2023-03-09
MX2024000761A (es) 2024-04-18
US20240352073A1 (en) 2024-10-24
WO2023288017A2 (en) 2023-01-19
AU2022310347A1 (en) 2024-02-29
CA3226492A1 (en) 2023-01-19
EP4370532A2 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
UY39527A (es) Composiciones de los inhibidores de peptidos del receptor de interleucina-23
MX2024000762A (es) Inhibidores peptidicos del receptor de interleucina-23.
UY39858A (es) Inhibidores peptídicos bicíclicos del receptor de interleucina-23
UY39857A (es) Inhibidores peptídicos lipidados del receptor de interleucina-23
ECSP22063238A (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
ECSP24014832A (es) Inhibidores de nlrp3
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
MX2024009477A (es) Inhibidores peptídicos del receptor de interleucina-23 y composiciones farmacéuticas de estos
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
SG10201810154WA (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CY1125216T1 (el) Δομηματα διανομης για διακυτωση και σχετικες μεθοδους
CL2024001756A1 (es) Inhibidores de cinasa met
MX2025008274A (es) Formulaciones de inhibidores peptidicos lipidados del receptor de interleucina-23
CL2025002026A1 (es) Inhibidores peptídicos del receptor de interleucina-23 (il-23r)
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
WO2024155547A3 (en) Peptide inhibitors of interleukin-23 receptor
DOP2025000151A (es) Inhibidores peptídicos del receptor de interleucina-23
UY40134A (es) Motor de presión negativa
MX2023003725A (es) Composiciones farmacéuticas y usos de las mismas para la prevención y/o tratamiento de la inflamación.
EA202092756A1 (ru) Конденсированные бициклические соединения для применения в качестве ингибиторов убиквитин-специфической пептидазы 30

Legal Events

Date Code Title Description
FB Suspension of granting procedure